Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects

Trial Profile

A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered Intramuscularly With or Without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or A/H7 IIV Naïve Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Influenza A virus H7N9 vaccines (Primary) ; AS03A
  • Indications Influenza A virus H7N9 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 13 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 06 Dec 2018 Planned initiation date changed from 3 Dec 2018 to 24 Dec 2018.
    • 20 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top